AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

AnaptysBio, Inc.NASDAQ: ANAB

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 151.9% from a year ago

Cash & equivalents stood at $248.47M at the end of Q1 FY2026, up 151.9% from a year earlier and up 4.3% from the prior quarter. Over 3 fiscal years it compounded at +49.5% a year.

Context

  • Cash & equivalents amounted to 75.4% of total assets at the end of Q1 FY2026, up 52.0 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +151.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$248.47M+4.3% QoQ
Last fiscal yearDec 2025
$238.2M+93.5% YoY
Year agoMar 2025
$98.64M+151.9% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+151.9%——
1 year+93.5%——
3-year CAGR+49.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
238.2M USD
Year-over-year change
+93.5%
4-year CAGR
-16.7%

Cash & Equivalents vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's Mar 2026 cash & equivalents of $248.47M is the 3rd highest of the 10 companies compared; the peer median is $50.75M.
  • Its year-over-year change of +151.9% is the 2nd highest of 10, against a peer median of +0.5%.
  • Cash & equivalents amounts to 75.4% of total assets for ANAB, versus a peer median of 66.6%.
ANAB Competitors Peer median
Cash & Equivalents for ANAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMVTImmunovant, Inc.Sep 2026$722.27M +38.4%+33.8%94.9%
MLTXMoonLake ImmunotherapeuticsMar 2026$298.49M +9.9%+103.8%74.6%
ANABAnaptysBio, Inc.Mar 2026$248.47M +151.9%+49.5%75.4%
ANNXAnnexon, Inc.Mar 2026$175.21M +80.4%+5.0%66.6%
DNTHDianthus Therapeutics, Inc.Jun 2026$110.55M +735.2%+49.3%9.1%
QTTBQ32 Bio Inc.Mar 2026$50.75M -22.5%+3.2%79.7%
XNCRXencor, Inc.Jun 2026$44.66M +0.5%+0.1%6.2%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M -51.0%-21.4%68.4%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M -5.6%-23.9%14.4%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$20.96M -31.1%-36.1%19.8%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ANAB) $50.75M+0.5%+3.2%66.6%

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents495.73M71.31M35.97M123.08M238.2M
Short-term Investments52.37M369.93M354.94M262.29M73.44M
Net Receivables876K1.42M6.85M40.77M33.85M
Inventory00000
Other Current Assets04.55M9.08M5.74M4.76M
Total Current Assets553.88M447.21M406.84M431.88M350.25M
Property, Plant & Equipment (Net)21.84M19.99M18.27M16.23M13.89M
Goodwill00000
Intangible Assets00000
Long-term Investments67.1M142.94M27.03M35.47M0
Tax Assets00000
Other Non-current Assets256K256K256K256K256K
Total Non-current Assets89.19M163.18M45.55M51.96M14.15M
Total Assets643.07M610.38M452.39M483.83M364.4M
Account Payables1.74M2.78M4.7M4M3.87M
Short-term Debt0001.93M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.18M5.38M23.77M31.05M11.09M
Total Current Liabilities16.1M26.05M37.44M45.43M38.63M
Long-term Debt000353.43M12.03M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities251.09M304.41M310.81M0276.53M
Total Non-current Liabilities270.54M322.23M326.84M367.54M288.56M
Total Liabilities286.64M348.28M364.29M412.97M327.19M
Common Stock28K29K27K30K28K
Retained Earnings(321.75M)(450.48M)(614.1M)(759.33M)(772.56M)
Accumulated OCI(422K)(5.25M)(797K)305K(24K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity356.43M262.1M88.1M70.87M37.21M
Total Debt20.96M19.45M17.81M369.46M14.11M
Net Debt(474.77M)(51.86M)(18.15M)246.38M(224.08M)

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.